ATE417841T1 - Furanderivate als ep4-rezeptorantagonisten - Google Patents

Furanderivate als ep4-rezeptorantagonisten

Info

Publication number
ATE417841T1
ATE417841T1 AT04768922T AT04768922T ATE417841T1 AT E417841 T1 ATE417841 T1 AT E417841T1 AT 04768922 T AT04768922 T AT 04768922T AT 04768922 T AT04768922 T AT 04768922T AT E417841 T1 ATE417841 T1 AT E417841T1
Authority
AT
Austria
Prior art keywords
optionally substituted
receptor antagonists
alkyl
group
furan derivatives
Prior art date
Application number
AT04768922T
Other languages
English (en)
Inventor
David Edward Clark
Neil Victor Harris
Garry Fenton
George Hynd
Keith Alfred James Stuttle
Jonathan Mark Sutton
Alexander William Oxford
Richard Jon Davis
Robert Alexander Coleman
Kenneth Lyle Clark
Original Assignee
Asterand Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterand Uk Ltd filed Critical Asterand Uk Ltd
Application granted granted Critical
Publication of ATE417841T1 publication Critical patent/ATE417841T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04768922T 2003-10-16 2004-10-15 Furanderivate als ep4-rezeptorantagonisten ATE417841T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0324269.0A GB0324269D0 (en) 2003-10-16 2003-10-16 EP4 receptor antagonists
US51220003P 2003-10-20 2003-10-20

Publications (1)

Publication Number Publication Date
ATE417841T1 true ATE417841T1 (de) 2009-01-15

Family

ID=29559424

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768922T ATE417841T1 (de) 2003-10-16 2004-10-15 Furanderivate als ep4-rezeptorantagonisten

Country Status (9)

Country Link
US (3) US7569602B2 (de)
EP (1) EP1673360B1 (de)
JP (1) JP2007508364A (de)
CN (1) CN1894231B (de)
AT (1) ATE417841T1 (de)
AU (1) AU2004281225B2 (de)
CA (1) CA2542440A1 (de)
GB (1) GB0324269D0 (de)
WO (1) WO2005037812A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US8080567B2 (en) 2005-08-09 2011-12-20 Asterand Uk Limited EP2 receptor agonists
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
CN101541778B (zh) 2006-08-11 2014-10-08 默克加拿大有限公司 作为ep4受体配体的噻吩甲酰胺衍生物
CA2672631A1 (en) * 2006-12-15 2008-06-19 Glaxo Group Limited Benzamide derivatives as ep4 receptor agonists
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
DE102008014523A1 (de) * 2008-03-15 2009-09-17 Robert Bosch Gmbh Heizgerät
PL2565191T3 (pl) * 2008-05-14 2015-03-31 Astellas Pharma Inc Pochodne kwasu 4-(indol-7-ilokarbonyloaminometylo)cykloheksanokarboksylowego jako antagoniści receptora EP4 użyteczni do leczenia przewlekłej niewydolności nerek lub nefropatii cukrzycowej
CA2733247C (en) * 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010087425A1 (ja) 2009-01-30 2010-08-05 国立大学法人京都大学 前立腺癌の進行抑制剤および進行抑制方法
MX367469B (es) 2010-06-07 2019-08-23 Novomedix Llc Compuestos furanilo y su uso.
PT3083554T (pt) * 2013-12-17 2019-06-11 Lilly Co Eli Compostos de ácido dimetilbenzóico
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
ES2896476T3 (es) 2017-05-18 2022-02-24 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
TWI768043B (zh) 2017-05-18 2022-06-21 瑞士商愛杜西亞製藥有限公司 N-取代吲哚衍生物
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
HRP20211533T1 (hr) 2017-05-18 2022-01-07 Idorsia Pharmaceuticals Ltd Derivati fenila kao modulatori receptora pge2
ES2927851T3 (es) * 2017-10-17 2022-11-11 Novartis Ag Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2767526B1 (fr) 1997-08-21 2002-10-04 Galderma Rech Dermatologique Composes bi-aromatiques relies par un radical heteroethynylene et compositions pharmaceutiques et cosmetiques les contenant
US6818666B2 (en) 1919-08-21 2004-11-16 Galderma Research & Development Bi-aromatic compounds linked via a heteroethylene radical, and pharmaceutical and cosmetic compositions using them
JP2839106B2 (ja) 1990-02-19 1998-12-16 キヤノン株式会社 電子写真感光体
HUT62894A (en) 1990-05-09 1993-06-28 Pfizer Process for producing azabenzimidazoles suitable for treating asthma, arthritis and similar diseases, as well as pharmaceuticql compositions comprising same
ATE204275T1 (de) 1990-06-07 2001-09-15 Astrazeneca Ab Indolderivate als 5-ht1-like agonisten
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
JPH04253974A (ja) 1991-02-05 1992-09-09 Ishihara Sangyo Kaisha Ltd スルホニル尿素系化合物、それらの製造方法及びそれらを含有する除草剤
US5356919A (en) 1991-05-30 1994-10-18 G. D. Searle & Co. Leukotriene B4 synthesis inhibitors
GB9116732D0 (en) 1991-08-02 1991-09-18 Fujisawa Pharmaceutical Co Indole derivatives
PT100902A (pt) 1991-09-26 1993-11-30 Smithkline Beecham Plc Derivados de mupirocina, uteis como agentes antibacterianos e antimicoplasmaticos,e processo para a sua preparacao
DE69303605T2 (de) 1992-03-27 1997-01-23 Schering Corp Unverbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung
GB9215361D0 (en) 1992-07-20 1992-09-02 Wellcome Found Heterocyclic compounds
GB9216009D0 (en) 1992-07-28 1992-09-09 Almirall Lab New indol derivatives
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
US5686445A (en) 1993-07-29 1997-11-11 American Cyanamid Company Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists
FR2713637B1 (fr) 1993-12-15 1996-01-05 Cird Galderma Nouveaux composés bi-aromatiques dérivés d'amide, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
GB9401994D0 (en) 1994-02-02 1994-03-30 Wellcome Found Heterocyclic compounds
JPH07281440A (ja) 1994-04-07 1995-10-27 Japan Synthetic Rubber Co Ltd カラーフィルタ用感放射線性組成物
GB9413758D0 (en) 1994-07-07 1994-08-24 Wellcome Found Heterocyclic compounds
US5883106A (en) 1994-10-18 1999-03-16 Pfizer Inc. 5-lipoxygenase inhibitors
SK281577B6 (sk) 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze
GB9500580D0 (en) 1995-01-12 1995-03-01 Merck Sharp & Dohme Therapeutic agents
US5834468A (en) 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
US5645566A (en) 1995-09-15 1997-07-08 Sub Q Inc. Apparatus and method for percutaneous sealing of blood vessel punctures
US5663357A (en) 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
FR2741878B1 (fr) 1995-12-01 1998-01-09 Cird Galderma Composes biaromatiques portant un groupement adamantyl en ortho, compositions pharmaceutiques et cosmetiques les contenant et utilisations
JPH09311401A (ja) 1996-05-24 1997-12-02 Konica Corp ハロゲン化銀写真感光材料
CA2263838A1 (en) 1996-08-21 1998-02-26 Sugen, Inc. Crystal structures of a protein tyrosine kinase
FR2759368B1 (fr) 1997-02-10 2001-06-01 Galderma Rech Dermatologique Composes biaromatiques, compositions les contenant et utilisations
IL132033A0 (en) 1997-04-04 2001-03-19 Pfizer Prod Inc Nicotinamide derivatives
JPH10287654A (ja) 1997-04-11 1998-10-27 Nissan Chem Ind Ltd ピラゾロン誘導体及び除草剤
WO1998047894A1 (en) 1997-04-24 1998-10-29 Dow Agrosciences Llc Pesticidal 3-(substituted phenyl)-5-(thienyl or furyl)-1,2,4-triazoles
DE69829966T2 (de) 1997-05-14 2006-02-09 Atherogenics, Inc. Ein monoether von probucol und methoden zur hemmung der vcam-1 expression
US6987113B2 (en) 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
FR2764604B1 (fr) 1997-06-13 1999-09-10 Cird Galderma Composes bi-aromatiques relies par un radical propynylene ou allenylene et compositions pharmaceutiques et cosmetiques les contenant
US6008362A (en) 1997-06-16 1999-12-28 Commons; Thomas Joseph Elevation of HDL cholesterol by 2-(-4-chlorol-1-aryl-butylidene)-hydrazinecarbothioamides
AU7589498A (en) 1997-06-16 1999-01-04 American Home Products Corporation Elevation of hdl cholesterol by 4-{(aminothioxomethyl)hydrazono}-4-arylbutyl carbamates
WO1998057928A1 (en) 1997-06-16 1998-12-23 American Home Products Corporation Elevation of hdl cholesterol by 2-(4-chloro -1-aryl-butylidene) -hydrazinecarbothioamides
AU7688398A (en) 1997-06-16 1999-01-04 American Home Products Corporation Elevation of hdl cholesterol by 2-{(aminothioxomethyl)-hydrazono}-2-arylethyl carbamates
US5977170A (en) 1997-06-16 1999-11-02 American Home Products Corporation Elevation of HDL cholesterol by 4-[(aminothioxomethyl)hydrazono]-4-arylbutyl carbamates
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
EP0962456B1 (de) 1997-09-26 2006-03-22 Toray Industries, Inc. Zyklische ketonderivate und ihre pharmazeutische verwendung
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
US6176864B1 (en) * 1998-03-09 2001-01-23 Corvascular, Inc. Anastomosis device and method
US6117791A (en) 1998-06-22 2000-09-12 Micron Technology, Inc. Etchant with selectivity for doped silicon dioxide over undoped silicon dioxide and silicon nitride, processes which employ the etchant, and structures formed thereby
CA2338490A1 (en) 1998-07-27 2000-02-10 Sergio Altamura Diketoacid-derivatives as inhibitors of polymerases
US6211197B1 (en) 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
CN1136218C (zh) 1998-10-23 2004-01-28 道农业科学公司 制备3-(取代的苯基)-5-(噻吩基或呋喃基)-1,2,4-三唑的方法以及在其中使用的新中间体
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
DE19922723A1 (de) 1999-05-18 2000-11-23 Clariant Gmbh Aktivmatrix-Displays mit hohem Kontrast
US6765004B1 (en) 1999-06-17 2004-07-20 Ortho-Mcneil Pharmaceutical, Inc. Indoloazepines as vasopressin receptor antagonists
ATE272398T1 (de) 1999-08-10 2004-08-15 Glaxo Group Ltd Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
US6541477B2 (en) 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
JP5278983B2 (ja) 1999-11-17 2013-09-04 塩野義製薬株式会社 アミド化合物の新規用途
JP4788939B2 (ja) * 1999-11-18 2011-10-05 味の素株式会社 新規フェニルアラニン誘導体
EP1108426A3 (de) 1999-12-02 2002-10-02 Pfizer Products Inc. Anwendung von Prostaglandinagonisten zur Behandlung der Erektionstörungen und Impotenz
SE9904676D0 (sv) 1999-12-20 1999-12-20 Astra Ab Novel compounds
IL141120A0 (en) 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US6506755B2 (en) 2000-02-03 2003-01-14 Hoffmann-La Roche Inc. Thiazolidinecarboxyl acids
KR20020076330A (ko) 2000-02-22 2002-10-09 오노 야꾸힝 고교 가부시키가이샤 안식향산 유도체, 이들의 제조 방법 및 이들을 유효성분으로서 함유하는 약제
WO2001064676A2 (en) 2000-02-28 2001-09-07 Scios, Inc. INHIBITORS OF p38-α KINASE
CA2402099C (en) 2000-03-24 2011-04-26 Pharmagene Laboratories Ltd. Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment
WO2002006278A1 (en) 2000-07-17 2002-01-24 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
PL360373A1 (en) 2000-08-08 2004-09-06 Ortho Mcneil Pharmaceutical, Inc. Non-imidazole aryloxypiperidines as h3 receptor ligands
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
AU2001286471B2 (en) 2000-08-29 2006-09-07 Allergan, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6291677B1 (en) 2000-08-29 2001-09-18 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US7217725B2 (en) 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
US6511999B2 (en) 2000-09-14 2003-01-28 Allergan, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
AU2002215222A1 (en) 2000-11-17 2002-05-27 Ishihara Sangyo Kaisha Ltd. Pyrimidine compounds or salts thereof, herbicides containing the compounds or the salts, methods for control of weeds by applying the same
DE10059864A1 (de) 2000-11-30 2002-06-13 Gruenenthal Gmbh Substituierte Amino-furan-2-yl-essigsäure- und Amino-thien-2-yl-essigsäure-Derivate
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10062086A1 (de) 2000-12-13 2002-07-04 Wella Ag Mittel und Verfahren zum Färben von Keratinfasern
EP1355640A1 (de) 2001-01-23 2003-10-29 Neurosearch A/S Verwendung von nicht kompetitiven und selektiven glur5-antagonisten als modulierende verbindungen des glutamatrezeptors
CA2435067C (en) 2001-01-26 2011-11-15 Chugai Seiyaku Kabushiki Kaisha Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
WO2002060898A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
DE60223544T2 (de) 2001-02-22 2008-09-25 University Of Bradford, Bradford Pyrrolo-indol- und pyrrolo-chinolin-derivate als prodrugs zur tumorbehandlung
WO2002067937A1 (en) 2001-02-22 2002-09-06 School Of Pharmacy, University Of London Indoline and tetrahydro-quinolines as prodrugs for tumour treatment
DE60211905T2 (de) 2001-02-22 2007-01-18 School Of Pharmacy, University Of London Benz-indol- und benzo-chinolin-derivate als prodrugs zur tumorbehandlung
DE10111262A1 (de) 2001-03-09 2002-09-12 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von Vinyl- Aryl- und Heteroarylessigsäuren und ihrer Devivate
JP3712111B2 (ja) * 2001-03-30 2005-11-02 ユーディナデバイス株式会社 電力増幅用半導体装置
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
CA2444031C (en) 2001-04-16 2012-02-21 Schering Corporation 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
DE10125145A1 (de) 2001-05-22 2002-11-28 Gruenenthal Gmbh Substituierte C-Furan-2-yl-methylamin- und C-Thiophen-2-yl-methylamin-Derivate
US20030027853A1 (en) 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US6956040B2 (en) 2001-07-16 2005-10-18 Ranbaxy Laboratories Limited Oxazolidinone piperazinyl derivatives as potential antimicrobials
US6562816B2 (en) 2001-08-24 2003-05-13 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
DE10150615A1 (de) 2001-10-12 2003-04-30 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
WO2003053352A2 (en) 2001-12-20 2003-07-03 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
WO2003055479A1 (en) 2001-12-21 2003-07-10 Consejo Superior De Investigaciones Cientificas Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
CA2473461C (en) 2002-01-11 2011-11-01 Sankyo Company, Limited Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
JP4771511B2 (ja) 2003-07-08 2011-09-14 第一三共株式会社 アミノアルコ−ル誘導体又はホスホン酸誘導体を含有する医薬組成物
US7101898B2 (en) 2002-02-01 2006-09-05 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
WO2003090869A1 (en) 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Lxr modulators
US6806265B2 (en) 2002-05-16 2004-10-19 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
WO2003097621A1 (en) 2002-05-17 2003-11-27 Qlt Inc. Methods of using thiazolidinedithione derivatives
JP2004051628A (ja) 2002-05-28 2004-02-19 Ishihara Sangyo Kaisha Ltd ピリジン系化合物又はその塩、それらの製造方法及びそれらを含有する除草剤
AU2003262947A1 (en) 2002-08-30 2004-03-19 Pharmacia And Upjohn Company Method of preventing or treating atherosclerosis or restenosis
DE10240261A1 (de) 2002-08-31 2004-03-11 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Halogen-Metall-Austauschreaktionen
DE10240262A1 (de) 2002-08-31 2004-03-11 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Aryllithium-Basen
AU2003290700A1 (en) 2002-11-22 2004-06-18 Smithkline Beecham Corporation Farnesoid x receptor agonists
US7365094B2 (en) 2002-12-23 2008-04-29 4Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
AU2003294376A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
GB0302094D0 (en) * 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
AU2003202753A1 (en) 2003-02-07 2004-08-30 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
JP2006519250A (ja) 2003-03-04 2006-08-24 ファイザー・プロダクツ・インク 医療処置におけるｅｐ２選択的受容体アゴニストの使用
AU2003215861A1 (en) 2003-04-07 2004-11-01 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
KR100696927B1 (ko) 2003-04-23 2007-03-20 니뽄 다바코 산교 가부시키가이샤 ＣａＳＲ 길항제
AU2003223034A1 (en) 2003-05-06 2004-11-26 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
US20040248957A1 (en) 2003-05-16 2004-12-09 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
WO2004108133A2 (en) 2003-06-05 2004-12-16 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
JP2005046141A (ja) 2003-07-11 2005-02-24 Sankyo Co Ltd リン酸エステルの製造方法
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists

Also Published As

Publication number Publication date
US20070135503A1 (en) 2007-06-14
WO2005037812A1 (en) 2005-04-28
EP1673360A1 (de) 2006-06-28
US7569602B2 (en) 2009-08-04
US7417068B2 (en) 2008-08-26
CA2542440A1 (en) 2005-04-28
JP2007508364A (ja) 2007-04-05
AU2004281225A1 (en) 2005-04-28
US20080306117A1 (en) 2008-12-11
GB0324269D0 (en) 2003-11-19
AU2004281225B2 (en) 2010-11-18
US20050124676A1 (en) 2005-06-09
CN1894231B (zh) 2011-10-05
CN1894231A (zh) 2007-01-10
EP1673360B1 (de) 2008-12-17

Similar Documents

Publication Publication Date Title
ATE417841T1 (de) Furanderivate als ep4-rezeptorantagonisten
AP1902A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
CO5611147A2 (es) Derivados de nicotinamida utiles como inhibidores p38
ECSP067013A (es) 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4
MXPA04004037A (es) Compuestos novedosos de 1, 2, 4-de triazol.
DE60022906D1 (de) Heterozyklische verbindungen mit sulfonamid-gruppen
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
ATE415160T1 (de) Modulatoren von peroxisome proliferator- aktivierten rezeptoren
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
CA2514220A1 (en) Ep4 receptor antagonists
MX2007009353A (es) Ciclohexilamidas como antagonistas de la dopamina d3, d2 y 5ht1a.
DE602004026071D1 (de) Aminopyrone und ihre verwendung als atm inhibitoren
MXPA05013652A (es) Modulador del receptor canabinoide.
NZ513594A (en) Heterocyclic compounds, intermediates thereof and elastase inhibitors
CO5640134A2 (es) Derivados de pirrol-2,5-ditiona como moduladores de receptor hepatico x
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
MX2010010471A (es) Derivado de tetrahidroisoquinolina novedoso.
DE60006583D1 (de) Neue verbindungen
WO2007017687A3 (en) Ep2 receptor agonists
ZA200500436B (en) 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
GB0215392D0 (en) Chemical compounds
TW200517394A (en) Method for stabilization of diarylvinylene compounds
ATE449773T1 (de) Homomorpholinoxazolidinone als antibakterielle mittel
TW200514559A (en) Novel use of cannabinoid receptor agonist
TNSN08521A1 (en) Phenylpentadienoyl derivatives and their use as par 1 antagonists

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties